학술논문
LBA4 Effect of post-study immunotherapy (IO) on overall survival (OS) outcome in patients with metastatic (m) NSCLC treated with first-line durvalumab (D) vs chemotherapy (CT) in the phase III MYSTIC study.
Document Type
Article
Author
Source
Subject
*CANCER chemotherapy
*IMMUNOTHERAPY
*SMALL cell lung cancer
*NON-small-cell lung carcinoma
*ACADEMIC medical centers
*
*
*
*
Language
ISSN
0923-7534